Loading...
•
Mar 31, 2024
Mersana Q1 2024 Earnings Report
Mersana reported financial results for Q1 2024 and provided a business update.
Key Takeaways
Mersana Therapeutics continues to advance its Phase 1 clinical trial of XMT-1660 and resumed patient recruitment in its Phase 1 clinical trial of XMT-2056. The company plans to share initial dose escalation and backfill cohort data and initiate the expansion portion of the trial in the second half of 2024.
Advanced Phase 1 clinical trial of XMT-1660, with plans to share initial data and initiate expansion in the second half of 2024.
Resumed patient recruitment for Phase 1 clinical trial of XMT-2056 after lifting of clinical hold.
Continued collaborations with Johnson & Johnson and Merck KGaA, Darmstadt, Germany.
Presented preclinical and clinical Dolasynthen data demonstrating potential to reduce adverse events.
Revenue by Segment
Forward Guidance
Mersana plans to share initial dose escalation and backfill cohort data and initiate the expansion portion of the trial in the second half of 2024. The company plans to advance dose escalation in this trial in 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...